These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10109799)

  • 41. Purchasing premixed products.
    Geberbauer CW
    J Healthc Mater Manage; 1988; 6(2):40, 42, 44-5. PubMed ID: 10286278
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [A modeling analysis of possible generic substitutions in an inpatient facility].
    Urbánek K; Vareková P
    Ceska Slov Farm; 1997 Apr; 46(2):74-7. PubMed ID: 9244566
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Documentation of the first steps of pediatric pharmaceutical care in a county hospital.
    Lal LS; Anassi EO; McCants E
    Hosp Pharm; 1995 Dec; 30(12):1107-8, 1111-2. PubMed ID: 10153657
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of cefmetazole, and cefoxitin for the treatment of patients hospitalized with acute urinary tract infections.
    Burke BM; Kessler DL; Cirulli C; Bracken RB
    J Antimicrob Chemother; 1989 Apr; 23 Suppl D():35-8. PubMed ID: 2722722
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Formulary conversion from glipizide to glyburide: a cost-minimization analysis.
    Nadel HL
    Hosp Pharm; 1995 Jun; 30(6):467-9, 472-4. PubMed ID: 10142848
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Automatic interchange policy for cefotetan and cefoxitin.
    Suzuki NT; Breuninger WB
    Am J Hosp Pharm; 1988 Sep; 45(9):1864. PubMed ID: 3228113
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical experience with cefmetazole sodium in the United States: an overview.
    Griffith DL; Novak E; Greenwald CA; Metzler CM; Paxton LM
    J Antimicrob Chemother; 1989 Apr; 23 Suppl D():21-33. PubMed ID: 2656625
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Financial impact of an aminoglycoside substitution program.
    Andrews JD; Stad K
    Can J Hosp Pharm; 1987 Feb; 40(1):23-6. PubMed ID: 10281256
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Economic impact of pharmacist's interventions: illustration in a rheumatology ward].
    Coursier S; Bontemps H; Brantus JF; Allenet B
    J Pharm Belg; 2008 Dec; 63(4):103-9. PubMed ID: 19320133
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The cost consequences of pharmacy reorganization.
    Beck B; Claghorn J; Sheldon R; Gaver K; Laritz M
    Hosp Formul; 1978 Mar; 13(3):220-1, 223. PubMed ID: 10306914
    [No Abstract]   [Full Text] [Related]  

  • 51. Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease.
    Hassan Y; Al-Ramahi RJ; Aziz NA; Ghazali R
    Ann Pharmacother; 2009 Oct; 43(10):1598-605. PubMed ID: 19776297
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The URV and the evaluation of new technologies].
    Sanjurjo Sáez M
    Farm Hosp; 2004; 28(5):384-6. PubMed ID: 15504097
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials.
    Taira DA; Seto TB; Siegrist R; Cosgrove R; Berezin R; Cohen DJ
    Am Heart J; 2003 Mar; 145(3):452-8. PubMed ID: 12660668
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension.
    Narine L; Hague LK; Walker JH; Vicente C; Schilz R; Desjardins O; Einarson TR; Iskedjian M
    Curr Med Res Opin; 2005 Dec; 21(12):2007-16. PubMed ID: 16368052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An automatic substitution policy for cefazolin.
    Nakagawa RS
    Can J Hosp Pharm; 1986 Aug; 39(4):105-6. PubMed ID: 10278469
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States.
    Jhaveri M; Seal B; Pollack M; Wertz D
    Curr Med Res Opin; 2007 Jun; 23(6):1431-43. PubMed ID: 17559740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
    Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacy-laboratory interactions: a unique method to control antibiotic costs.
    Goff D; Thornton J
    Hosp Pharm; 1989 Jan; 24(1):26-9, 32. PubMed ID: 10291600
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of drug costs within diagnosis related groups.
    Kolar R; Stanaszek W; Osborne J; Dougherty K
    Hosp Pharm; 1984 Nov; 19(11):731-5. PubMed ID: 10310864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.